TL;DR: Tranexamic acid is a prescription antifibrinolytic drug, used in surgery to control bleeding, and used at five hundred to one thousand five hundred milligrams orally to treat melasma. The two to three percent topical serums you can buy at Sephora are the same molecule. The oral data is good. The topical data is real but smaller. Here is what the studies actually show and where the marketing has run ahead of the evidence.
A patient brought me a bottle last March. Three-percent tranexamic acid serum, marketed for melasma, ninety dollars at a chain pharmacy. She wanted to know whether it was the same drug her cousin was taking orally on a dermatologist’s prescription for the same condition. It was. She wanted to know whether she was getting the same effect. She was not, or at least not the same magnitude, and the gap between the two is most of what this piece is about.
Tranexamic acid is one of the more interesting molecules to enter the cosmetic skincare aisle in the last decade. It is interesting because it has serious clinical evidence at oral doses, because the topical evidence is meaningful but more modest than the marketing suggests, and because the drug is technically available without prescription in the United States only when it is sold as a cosmetic. Buy it as a melasma serum and no one asks any questions. Buy it as a heavy-menstrual-bleeding tablet and you need a doctor. The molecule is identical.
This is a piece about that gap, and about how to think clearly about a serum that contains a real drug.
What tranexamic acid actually does
Tranexamic acid is an antifibrinolytic agent. It blocks the conversion of plasminogen to plasmin, which is the enzyme that breaks down blood clots. Its original medical use was, and still is, controlling surgical bleeding and treating heavy menstrual bleeding. Cyclokapron is the brand name most people see. The connection to skin pigmentation came up almost by accident in the 1970s, when Japanese dermatologists noticed that women taking oral tranexamic acid for menstrual bleeding sometimes saw their melasma fade.
The mechanism by which it affects pigmentation is not the same mechanism by which it affects bleeding. Plasmin, the enzyme tranexamic acid inhibits, is also involved in the UV-triggered melanocyte activation cascade. Specifically, UV exposure releases plasminogen activator, which generates plasmin, which contributes to the release of inflammatory mediators that drive melanocyte stimulation. Block plasmin and you blunt one branch of the UV-to-pigment signaling pathway. Taraz, Niknam, and Ehsani’s 2017 review (PMID: 28133910) walks through the mechanism more thoroughly than I will here.
This is a different mechanism than hydroquinone, which inhibits tyrosinase directly, and a different mechanism than vitamin C, which interrupts melanin synthesis at a different step. The clinical implication is that tranexamic acid can be combined with other depigmenting agents without redundancy, which is part of why it has become a popular ingredient in multi-active melasma protocols.
What the studies actually show
The oral tranexamic acid data is the strongest data we have. Bala and colleagues’ 2018 review (PMID: 29677015) summarizes the literature. The typical oral dose for melasma is 500 to 1500 milligrams per day, divided across two or three doses, for two to six months. The response rate across the studies in the review is in the sixty to ninety percent range, with the majority showing significant melasma improvement at twelve weeks. The side-effect profile is generally good in selected patients. The exclusion criteria are real and matter: history of thrombosis, hormonal contraceptives at higher-risk formulations, pregnancy, smoking history with cardiovascular risk factors, and several others. This is a real drug with real contraindications.
Kim and colleagues’ 2017 meta-analysis (PMID: 28429035) pools the available randomized trials and lands at a similar conclusion. Oral tranexamic acid produces meaningful melasma improvement compared with placebo, comparable in many studies to hydroquinone monotherapy. The treatment effect is durable for some patients and rebounds in others after discontinuation. UV protection is the load-bearing variable for durability.
The topical literature is smaller. Atefi and colleagues’ 2017 trial (PMID: 28748406) compared topical three-percent tranexamic acid against four-percent hydroquinone in women with melasma over twelve weeks. Both improved melasma. Topical tranexamic acid was non-inferior to hydroquinone on the primary outcome and had a better side-effect profile. This is the most-cited topical trial, and it is reasonably designed.
The Lueangarun and colleagues 2020 pilot trial (PMID: 31840921) tested intradermal injected tranexamic acid for melasma. The injections produced significant improvement. This is a different delivery route than the over-the-counter serum, and the comparison is not directly translatable, but it speaks to dose-response: tranexamic acid works better the more of it gets into the skin, and topical application is the lowest-delivery method of the three studied routes.
What the topical literature does not yet have is a large, long-term, multi-center trial at consumer-realistic concentrations. The Atefi trial used three percent. The serums on the shelf at Sephora vary from two to five percent. The percentages are similar. The vehicle differences across products are large and underreported, and vehicle drives penetration as much as concentration does.
The gap between oral and topical
This is the part that the marketing on most tranexamic acid serums avoids. Oral tranexamic acid achieves systemic concentrations that result in plasma levels capable of meaningfully blunting the UV-plasmin-melanocyte cascade across the entire skin surface. Topical tranexamic acid achieves local skin concentrations that are smaller in magnitude and limited to the area of application.
Both work. They do not work to the same degree. The oral data shows a treatment effect at twelve weeks of roughly fifty to seventy percent improvement in melasma severity indices in responders. The topical data, in the Atefi trial and the smaller follow-ups, shows improvement in the thirty to fifty percent range over the same period. These are not the same magnitude of effect, and the safety question is different.
The honest framing for a consumer is this. If your melasma is mild to moderate, has not responded to sun protection and basic actives, and you are not a candidate for oral tranexamic acid because of contraindications, the topical serum is a reasonable addition to your protocol. If your melasma is moderate to severe and you do not have oral contraindications, a conversation with a dermatologist about oral tranexamic acid is the more evidence-based path. Topical is not a substitute for oral. It is an adjunct.
The over-the-counter problem
There is a regulatory inconsistency worth noting. Tranexamic acid is a prescription drug for its original indication (bleeding) in the United States. It is sold over the counter as a cosmetic ingredient with the same chemistry, in the same molecule, at concentrations that produce clinically meaningful skin effects. This is not unique to tranexamic acid. Hydrocortisone, salicylic acid, and adapalene have similar regulatory split personalities. But tranexamic acid is the example where the gap between the pharmaceutical and the cosmetic shelf is the largest.
What this means in practice. If you are buying a tranexamic acid serum, you are buying a drug. You are not buying a moisturizer or a hydrator. The formulation quality matters more than it does for inert categories, because the active is doing real biochemistry in your skin. The percentages matter. The vehicle matters. The pH matters. And the absence of patient screening matters, which is to say nobody is asking you about your clotting history or your hormonal status before you check out, because cosmetic regulations do not require it.
For most people, the topical does not produce systemic absorption sufficient to be concerned about. The handful of pharmacokinetic studies on topical tranexamic acid show very low systemic levels. The caveat is application area. A face-only application is one thing. A whole-body application, or use on broken or inflamed skin, can increase absorption in ways that have not been thoroughly characterized.
How I actually use it
In my own routine, tranexamic acid sits as a secondary active in the morning, layered after vitamin C and before sunscreen. Two to three percent products are what I have used. I do not stack it with retinoids in the same routine because the combined irritation can worsen the pigmentation it is supposed to treat. I have used it in alternation with azelaic acid in the evening, which is a combination I find well tolerated.
The pattern I have seen, in myself and in patient anecdotes that match the published trials, is gradual improvement over eight to sixteen weeks. The early weeks are unimpressive. The improvement, if it is going to happen, shows up around week ten and continues through week twenty. Sun protection is the variable that gates the whole thing. I would rather a patient be on conservative sun protection without topical tranexamic acid than on the serum without the sunscreen.
For patients with severe melasma who have not responded to topical protocols, I will note the oral option exists and is well-studied, but the conversation belongs with a dermatologist who can evaluate the contraindications, not in a journal piece.
What I would tell my past self
Take the molecule seriously. Tranexamic acid is a real drug doing real biochemistry. The marketing copy that calls it a brightening ingredient understates what it is. The bottle on your bathroom shelf contains the same chemistry that surgeons use to control bleeding. The dose is different. The effect on skin is real.
Set realistic expectations. The topical serum is not the oral tablet. The treatment effect is meaningful but smaller. Two months is not enough time to evaluate. Four months is the honest window, and sun protection is the variable that determines whether the four months pay off.
Combine it with the rest of the protocol. Tranexamic acid alone is not a melasma solution. It is one component of a stack that includes sun protection, sometimes azelaic acid, sometimes a retinoid in alternating routines, and behavioral changes about UV exposure that no serum will compensate for. The combination protocols out-perform any single agent in the available trials.
If your melasma is severe, talk to a dermatologist. The oral evidence is better than the topical evidence. The screening for contraindications is real and worth taking through a clinical consultation. The over-the-counter serum is a useful adjunct, not a stand-in for the conversation.
FAQ
Is topical tranexamic acid safe during pregnancy?
The data is limited and the cautious clinical default is to hold both oral and topical tranexamic acid during pregnancy. The systemic absorption from topical use is small but not zero, and pregnancy melasma is typically managed with sun protection and post-delivery topical treatment rather than pregnancy-window intervention.
How long until I see results from topical tranexamic acid?
Eight to sixteen weeks for meaningful improvement, with most published trials running twelve weeks as the primary endpoint. If you have seen nothing at sixteen weeks, the topical is probably not delivering enough to your particular pigmentation pattern.
Can I use tranexamic acid with retinol or other actives?
With vitamin C, niacinamide, and azelaic acid, yes, well tolerated in most patients. With retinoids in the same routine, the combined irritation can worsen melasma. Alternating nights is the conservative protocol.
Is the over-the-counter version weaker than the prescription?
The molecule is identical. The dose and the delivery route are different. Oral tranexamic acid produces a larger and more uniform treatment effect than topical at consumer-realistic concentrations. The topical is real but smaller in magnitude.
Does tranexamic acid work on post-inflammatory hyperpigmentation as well as melasma?
The literature on post-inflammatory hyperpigmentation specifically is smaller. The mechanism overlaps (UV-plasmin signaling is involved in both), and clinical use suggests modest efficacy. Mandelic and azelaic acids have more direct evidence for post-inflammatory hyperpigmentation in skin of color.
Related Elelaf tools
Sources
- Bala HR, Lee S, Wong C, Pandya AG, Rodrigues M. ‘Oral tranexamic acid for the treatment of melasma: a review.’ Dermatologic Surgery, 2018;44(6):814-825. PMID: 29677015.
- Kim HJ, Moon SH, Cho SH, Lee JD, Kim HS. ‘Efficacy and safety of tranexamic acid in melasma: a meta-analysis and systematic review.’ Acta Dermato-Venereologica, 2017;97(7):776-781. PMID: 28429035.
- Taraz M, Niknam S, Ehsani AH. ‘Tranexamic acid in treatment of melasma: a comprehensive review of clinical studies.’ Dermatologic Therapy, 2017;30(3):e12465. PMID: 28133910.
- Atefi N, Dalvand B, Ghassemi M, Mehran G, Heydarian A. ‘Therapeutic effects of topical tranexamic acid in comparison with hydroquinone in treatment of women with melasma.’ Dermatology and Therapy, 2017;7(3):417-424. PMID: 28748406.
- Lueangarun S, Sirithanabadeekul P, Wongwicharn P, et al. ‘Intradermal tranexamic acid injection for melasma: a pilot clinical trial.’ Journal of Cosmetic Dermatology, 2020;19(7):1665-1670. PMID: 31840921.